Compare Amgen, Inc. (AMGN) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $13.08. The key difference: Amgen, Inc. pays a 2.77% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | MSTZ | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $27.92 |
52-Week Low | $271.18 | $3.12 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MSTZ trades at $12.525, down 1.53% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. Key support lies at $12 and resistance at $13. Recent news highlights ETF performance unrelated to AI, but specific company financials are unavailable in the provided data, limiting fundamental assessment.
The outlook for MSTZ is mixed; technical strength suggests potential upside if it breaks resistance, but the absence of fundamental data like P/E or revenue growth poses significant uncertainty. Risks include market volatility and lack of visibility into business performance, requiring careful evaluation of upcoming earnings reports for clearer direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
